ArticleIn vivo (Athens, Greece)
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe standard of care for patients with muscle-invasive bladder cancer (MIBC) is treatment with radical cystectomy (RC) and perioperative platinum-based chemotherapy (neoadjuvant or adjuvant). Perioperative treatment can improve overall survival (OS), and the most robust evidence favors neoadjuvant chemotherapy (NAC). The RealBLADDER study assessed the efficacy and safety of perioperative chemotherapy in patients with MIBC in an Italian real-world setting. PATIENTS AND
methodsRealBLADDER enrolled patients with MIBC treated with perioperative chemotherapy from June 2018 to June 2023. The primary endpoint was the rate of non-invasive downstaging (NID) (ypT0/pTis/pTaN0 or <ypT1N0) and complete pathological response (pCR) (yp0N0), defined as the absence of residual tumor cells in the bladder and lymph nodes at the pathological examination after NAC. Secondary endpoints were disease-free survival (DFS), OS and surgical outcomes.
resultsA total of 173 eligible patients were identified. One hundred and thirty-seven patients (79.2%) received NAC and 36 (20.8%) received adjuvant chemotherapy (AC). The NID rate was 36.8%, and pCR achieved in 33.6% of patients treated with NAC. The rate of surgical morbidity and mortality were 20.9% and 0%, respectively. The 12-month DFS was 73.7% [95% confidence interval (CI)=0.672-0.808]. The 12-month OS rate in the entire population was 92.1% (95%CI=0.880-0.963). Compared to AC, DFS was improved in patients treated with NAC (
conclusionNAC is associated with an improved DFS compared to AC, a high rate of NID and pCR and low rate of surgical morbidity and mortality, supporting NAC as the preferred perioperative strategy for MIBC in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.